Please try another search
Cessatech A/S engages in identifying and developing drugs for the treatment of medical unmet need in children in Denmark. The company’s lead product is CT001, an analgesic nasal spray for the treatment of acute and planned painful procedures in children. It also develops CT002, a nasal spray for magnetic resonance imaging scanning; and CT003, a local anesthetic gel. The company has a collaboration and license agreement with Ventis Pharma Corporation to develop and formulate pain management therapies. Cessatech A/S was incorporated in 2020 and is based in Copenhagen, Denmark.
Name | Age | Since | Title |
---|---|---|---|
Rachel Curtis Graversen | - | 2022 | Director |
Martin Olin | 54 | 2020 | Independent Chairman of the Board |
Peter Birk | 59 | 2020 | Independent Director |
Charlotte Videbaek | 62 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review